46-2822493 · San Diego, CA
THE ORGANIZATION CONDUCTS RESEARCH AND TRIALS FOR DELIVERY OF PERSONALIZEDMEDICINE THROUGH A REGENERATIVE PROCESS AND THE UTILIZATION OF ARTIFICIALINTELLIGENCE. THIS RESEARCH IS CONDUCTED THROUGH THE USE OF TRANSDISCIPLINARYAPPROACHES FOR PRE-SYMPTOMATIC DETECTION AND PERSONALIZED THERAPEUTICS FOR VARIOUSCANCER AND AUTOIMMUNE DISORDER TREATMENTS.
Total revenue
$1.1M
FY2023
Total expenses
$855.4K
FY2023
Net assets
$895.3K
FY2023
Operating margin
19.5%
NPLens analysis
FY19–FY2023 · from annual filings
Financial health
A+
Derived analysis — not an official IRS designation.
Computed from FY2023 · derived analysis
FY2023 · program vs. administration vs. fundraising (Form 990, Part IX)
FY2023 · where revenue comes from (as reported)
Highest-paid officers, directors & key employees · FY2023.
SHASHAANKA ASHILI
CEO
$75,644
JAYA MINI GILL
Executive Dir.
$15,372
MARLON SARIA
Secretary
$0
BEN WILLIAMS
Director
$0
BOB HOTTO
Director
$0
Each figure on this page traces to one of these source returns.
Health scores, efficiency ratios, peer percentiles, and outlier flags are derived analysis by NPLens — not official IRS designations. Figures are as reported on the organization's Form 990 filings. How these are computed →